Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Michael Diamond and Rita Chen.
Michael Diamond
Connection Strength
5.328
Rita Chen
  1. In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. Nature. 2021 08; 596(7870):103-108.
    View in: PubMed
    Score: 0.952
  2. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat Med. 2021 04; 27(4):717-726.
    View in: PubMed
    Score: 0.933
  3. An intranasal vaccine durably protects against SARS-CoV-2 variants in mice. Cell Rep. 2021 07 27; 36(4):109452.
    View in: PubMed
    Score: 0.239
  4. Ultrapotent miniproteins targeting the SARS-CoV-2 receptor-binding domain protect against infection and disease. Cell Host Microbe. 2021 07 14; 29(7):1151-1161.e5.
    View in: PubMed
    Score: 0.238
  5. A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques. Cell Rep Med. 2021 04 20; 2(4):100230.
    View in: PubMed
    Score: 0.234
  6. Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection. Cell. 2021 04 01; 184(7):1804-1820.e16.
    View in: PubMed
    Score: 0.232
  7. Publisher Correction: SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat Immunol. 2020 Nov; 21(11):1470.
    View in: PubMed
    Score: 0.228
  8. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat Immunol. 2020 11; 21(11):1327-1335.
    View in: PubMed
    Score: 0.225
  9. A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2. Cell. 2020 10 01; 183(1):169-184.e13.
    View in: PubMed
    Score: 0.225
  10. Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in Mice. Cell Host Microbe. 2020 09 09; 28(3):465-474.e4.
    View in: PubMed
    Score: 0.224
  11. Growth, detection, quantification, and inactivation of SARS-CoV-2. Virology. 2020 09; 548:39-48.
    View in: PubMed
    Score: 0.222
  12. A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies. Cell. 2020 08 06; 182(3):744-753.e4.
    View in: PubMed
    Score: 0.222
  13. Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques. Proc Natl Acad Sci U S A. 2021 09 21; 118(38).
    View in: PubMed
    Score: 0.061
  14. A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants. Immunity. 2021 09 14; 54(9):2159-2166.e6.
    View in: PubMed
    Score: 0.060
  15. Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals. Cell Rep. 2021 08 24; 36(8):109604.
    View in: PubMed
    Score: 0.060
  16. Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations. J Mol Biol. 2021 09 17; 433(19):167177.
    View in: PubMed
    Score: 0.060
  17. Assessment of serological assays for identifying high titer convalescent plasma. Transfusion. 2021 09; 61(9):2658-2667.
    View in: PubMed
    Score: 0.060
  18. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature. 2021 08; 596(7870):109-113.
    View in: PubMed
    Score: 0.060
  19. Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. Cell Rep Med. 2021 06 15; 2(6):100313.
    View in: PubMed
    Score: 0.059
  20. SARS-CoV-2 exacerbates proinflammatory responses in myeloid cells through C-type lectin receptors and Tweety family member 2. Immunity. 2021 06 08; 54(6):1304-1319.e9.
    View in: PubMed
    Score: 0.059
  21. Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein. Cell. 2021 04 29; 184(9):2316-2331.e15.
    View in: PubMed
    Score: 0.058
  22. The antigenic anatomy of SARS-CoV-2 receptor binding domain. Cell. 2021 04 15; 184(8):2183-2200.e22.
    View in: PubMed
    Score: 0.058
  23. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe. 2021 03 10; 29(3):477-488.e4.
    View in: PubMed
    Score: 0.058
  24. Association between SARS-CoV-2 Neutralizing Antibodies and Commercial Serological Assays. Clin Chem. 2020 12 01; 66(12):1538-1547.
    View in: PubMed
    Score: 0.057
  25. Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. Science. 2020 11 20; 370(6519):950-957.
    View in: PubMed
    Score: 0.057
  26. De novo design of picomolar SARS-CoV-2 miniprotein inhibitors. Science. 2020 10 23; 370(6515):426-431.
    View in: PubMed
    Score: 0.056
  27. Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2. Proc Natl Acad Sci U S A. 2020 08 25; 117(34):20803-20813.
    View in: PubMed
    Score: 0.056
  28. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature. 2020 08; 584(7821):443-449.
    View in: PubMed
    Score: 0.056
  29. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med. 2020 09; 26(9):1422-1427.
    View in: PubMed
    Score: 0.056
  30. Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. Cell Host Microbe. 2020 09 09; 28(3):475-485.e5.
    View in: PubMed
    Score: 0.056
  31. A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection. J Immunol. 2020 08 15; 205(4):915-922.
    View in: PubMed
    Score: 0.056
  32. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020 07; 583(7815):290-295.
    View in: PubMed
    Score: 0.055
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.